Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 41, Issue 2, 2003, Pages 221-226

  Kim, Sang We ^a   Suh, Cheolwon ^a   Lee, Sang Do ^a   Kim, Woo Sung ^a   Kim, Dong Soon ^a   Kim, Won Dong ^a   Lee, Jung Sin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cisplatin; Non small cell lung cancer; Paclitaxel; Weekly low dose chemotherapy

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TOXICITY; WEIGHT GAIN;

EID: 0037829155     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00192-2     Document Type: Article

References (28)

1. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:(7):2000;1878-1886.
2. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev. 19:(1-2):2000;67-73.
3. Arbuck S.G. Paclitaxel: what schedule? What dose? J. Clin. Oncol. 12:(2):1994;233-236.
4. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18:(3):2000;623-631.
5. Rowinsky E.K., Jiroutek M., Bonomi P., Johnson D., Baker S.D. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin. Cancer Res. 5:(4):1999;767-774.
6. Klastersky J., Sculier J.P., Ravez P., Libert P., Michel J., Vandermoten G., et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J. Clin. Oncol. 4:(12):1986;1780-1786.
7. Simon R. How large should a phase II trial of a new drug be? Cancer Treat. Rep. 71:(11):1987;1079-1085.
8. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13:(1):1995;180-190.
9. Rowinsky E., Mackey M., Sn G. Metaanalysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;284.
10. Yeung T.K., Germond C., Chen X., Wang Z. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem. Biophys. Res. Commun. 263:(2):1999;398-404.
11. Das G.C., Holiday D., Gallardo R., Haas C. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett. 165:(2):2001;147-153.
12. Georgiadis M.S., Schuler B.S., Brown J.E., Kieffer L.V., Steinberg S.M., Wilson W.H., et al. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. J. Clin. Oncol. 15:(2):1997;735-743.
13. Kim R., Osaki A., Toge T. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. Oncol. Rep. 8:(5):2001;1171-1176.
14. Aisner J., Belani C.P., Kearns C., Conley B., Hiponia D., Engstrom C., et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin. Oncol. 22:(5 Suppl. 12):1995;17-21.
15. Choy H., Akerley W., Safran H., Clark J., Rege V., Papa A., et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 12:(12):1994;2682-2686.
16. Chang A.Y., Rubins J., Asbury R., Boros L., Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semin. Oncol. 28:(4 Suppl. 14):2001;10-13.
17. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:(11):1996;1843-1849.
18. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:(1):1997;81-86.
19. Kano Y., Akutsu M., Tsunoda S., Suzuki K., Yazawa Y. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother. Pharmacol. 37:(6):1996;525-530.
20. Niho S., Ohe Y., Kakinuma R., Kubota K., Matsumoto T., Ohmatsu H., et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer. 35:(2):2002;209-214.
21. Jagasia M.H., Langer C.J., Johnson D.H., Yunus F., Rodgers J.S., Schlabach L.L., et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin. Cancer Res. 7:(1):2001;68-73.
22. Lippe P., Tummarello D., Monterubbianesi M.C., Silva R.R., Giuliodori L., Mari D., et al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann. Oncol. 10:(2):1999;217-221.
23. Akerley W. III. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest. 117:(4 Suppl. 1):2000;152S-155S.
24. Akerley W., Choy H., Safran H., Sikov W., Rege V., Sambandam S., et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin. Oncol. 24:(4 Suppl. 12):1997;S12-10-S12-13.
25. Chang A.Y., Boros L., Asbury R., Hui L., Rubins J. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin. Oncol. 24:(5 Suppl. 17):1997;S17-69-S17-71.
26. Koumakis G., Demiri M., Barbounis V., Vassilomanolakis M., Gontikakis E., Pamouksoglou P., et al. Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer. 35:(3):2002;315-317.
27. Rowinsky E.K., Chaudhry V., Forastiere A.A., Sartorius S.E., Ettinger D.S., Grochow L.B., et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 11:(10):1993;2010-2020.
28. Ota S., Sugiyama T., Ushijima K., Komai K., Fujiyoshi K., Hirai N., et al. Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel. Cancer Lett. 160:(1):2000;9-12.